Implication of β2-adrenergic Receptor and MiR-196a Correlation in Neurite Outgrowth of LNCaP Prostate Cancer Cells

Overview

Journal PLoS One

Specialties General Medicine
Science

Date 2021 Jun 30

PMID 34191854

Citations 3

Authors

Ilaria Guerriero

Hakon Ramberg

Krizia Sagini

Manuel Ramirez-Garrastacho

Kristin A Tasken

Alicia Llorente

Affiliations

Soon will be listed here.

Abstract

The β2-adrenergic receptor has been shown to be involved in neuroendocrine differentiation and to contribute to the development of aggressive prostate cancer. In this study we have investigated whether miR-196a plays a role in the regulation of the β2-adrenergic receptor in the LNCaP prostate cancer cell line. Our results show that the expression of miR-196a is elevated in LNCaP prostate cancer cells with reduced levels of β2-adrenergic receptor after stably transfection with three different shRNAs. Furthermore, treatment with β-blockers showed that this upregulation is strictly related to the low levels of β2-adrenergic receptor and not to the inhibition of the receptor signaling activity. Finally, we found that the reduced ability of LNCaP cells with low levels of β2-adrenergic receptor to initiate neuroendocrine differentiation under androgen depletion conditions is mediated by miR-196a. In conclusion, this study provides the rational for a role of miR-196a in the β2-adrenergic receptor mediated neuroendocrine differentiation of LNCaP prostate cancer cells.

Citing Articles

Understanding the function of Pax5 in development of docetaxel-resistant neuroendocrine-like prostate cancers.

Bhattacharya S, Harris H, Islam R, Bodas S, Polavaram N, Mishra J Cell Death Dis. 2024; 15(8):617.

PMID: 39183332 PMC: 11345443. DOI: 10.1038/s41419-024-06916-y.

Inhibition of β2-adrenergic receptor regulates necroptosis in prostate cancer cell.

Wu S, Li M, Chen F, Zeng Y, Xu C Heliyon. 2024; 10(11):e31865.

PMID: 38845899 PMC: 11153256. DOI: 10.1016/j.heliyon.2024.e31865.

Exploring the Potential of Rosemary Derived Compounds (Rosmarinic and Carnosic Acids) as Cancer Therapeutics: Current Knowledge and Future Perspectives.

Sirajudeen F, Bou Malhab L, Bustanji Y, Shahwan M, Alzoubi K, Semreen M Biomol Ther (Seoul). 2023; 32(1):38-55.

PMID: 38148552 PMC: 10762267. DOI: 10.4062/biomolther.2023.054.

References

Ambs S, Prueitt R, Yi M, Hudson R, Howe T, Petrocca F . Genomic profiling of microRNA and messenger RNA reveals deregulated microRNA expression in prostate cancer. Cancer Res. 2008; 68(15):6162-70. PMC: 2597340. DOI: 10.1158/0008-5472.CAN-08-0144. View

Her L, Mao S, Chang C, Cheng P, Chang Y, Yang H . miR-196a Enhances Neuronal Morphology through Suppressing RANBP10 to Provide Neuroprotection in Huntington's Disease. Theranostics. 2017; 7(9):2452-2462. PMC: 5525749. DOI: 10.7150/thno.18813. View

Merkle D, Hoffmann R . Roles of cAMP and cAMP-dependent protein kinase in the progression of prostate cancer: cross-talk with the androgen receptor. Cell Signal. 2010; 23(3):507-15. DOI: 10.1016/j.cellsig.2010.08.017. View

Morote J, Comas I, Planas J . Re: Nicolas Mottet, Joaquim Bellmunt, Erik Briers, et al. EAU-ESTRO-ESUR-SIOG Guidelines on Prostate Cancer. European Association of Urology; 2017. http://uroweb.org/guideline/prostate-cancer: How to Assess the Efficacy of Medical Castration. Eur Urol. 2018; 73(5):e134-e135. DOI: 10.1016/j.eururo.2018.01.039. View

Huang Y, Jiang X, Liang X, Jiang G . Molecular and cellular mechanisms of castration resistant prostate cancer. Oncol Lett. 2018; 15(5):6063-6076. PMC: 5876469. DOI: 10.3892/ol.2018.8123. View

Yu J, Cao Q, Mehra R, Laxman B, Yu J, Tomlins S . Integrative genomics analysis reveals silencing of beta-adrenergic signaling by polycomb in prostate cancer. Cancer Cell. 2007; 12(5):419-31. DOI: 10.1016/j.ccr.2007.10.016. View

Zhao H, Ma T, Lin J, Liu L, Sun W, Guo L . Identification of valid reference genes for mRNA and microRNA normalisation in prostate cancer cell lines. Sci Rep. 2018; 8(1):1949. PMC: 5792445. DOI: 10.1038/s41598-018-19458-z. View

Braadland P, Ramberg H, Grytli H, Urbanucci A, Nielsen H, Guldvik I . The β-Adrenergic Receptor Is a Molecular Switch for Neuroendocrine Transdifferentiation of Prostate Cancer Cells. Mol Cancer Res. 2019; 17(11):2154-2168. DOI: 10.1158/1541-7786.MCR-18-0605. View

Dai C, Heemers H, Sharifi N . Androgen Signaling in Prostate Cancer. Cold Spring Harb Perspect Med. 2017; 7(9). PMC: 5580512. DOI: 10.1101/cshperspect.a030452. View

10.

Nevedomskaya E, Baumgart S, Haendler B . Recent Advances in Prostate Cancer Treatment and Drug Discovery. Int J Mol Sci. 2018; 19(5). PMC: 5983695. DOI: 10.3390/ijms19051359. View

11.

Lipianskaya J, Cohen A, Chen C, Hsia E, Squires J, Li Z . Androgen-deprivation therapy-induced aggressive prostate cancer with neuroendocrine differentiation. Asian J Androl. 2014; 16(4):541-4. PMC: 4104077. DOI: 10.4103/1008-682X.123669. View

12.

Braadland P, Grytli H, Ramberg H, Katz B, Kellman R, Gauthier-Landry L . Low β₂-adrenergic receptor level may promote development of castration resistant prostate cancer and altered steroid metabolism. Oncotarget. 2015; 7(2):1878-94. PMC: 4811504. DOI: 10.18632/oncotarget.6479. View

13.

Bartel D . MicroRNAs: genomics, biogenesis, mechanism, and function. Cell. 2004; 116(2):281-97. DOI: 10.1016/s0092-8674(04)00045-5. View

14.

Lu Y, Chang J, Chan E, Chao Y, Yeh T, Chen J . miR-196, an Emerging Cancer Biomarker for Digestive Tract Cancers. J Cancer. 2016; 7(6):650-5. PMC: 4829550. DOI: 10.7150/jca.13460. View

15.

Zhao Y, Li W . Beta-adrenergic signaling on neuroendocrine differentiation, angiogenesis, and metastasis in prostate cancer progression. Asian J Androl. 2018; 21(3):253-259. PMC: 6498733. DOI: 10.4103/aja.aja_32_18. View

16.

Ramberg H, Eide T, Krobert K, Levy F, Dizeyi N, Bjartell A . Hormonal regulation of beta2-adrenergic receptor level in prostate cancer. Prostate. 2008; 68(10):1133-42. DOI: 10.1002/pros.20778. View

17.

Rodriguez M, Bajo-Santos C, Hessvik N, Lorenz S, Fromm B, Berge V . Identification of non-invasive miRNAs biomarkers for prostate cancer by deep sequencing analysis of urinary exosomes. Mol Cancer. 2017; 16(1):156. PMC: 5629793. DOI: 10.1186/s12943-017-0726-4. View

18.

Seng S, Avraham H, Jiang S, Venkatesh S, Avraham S . KLHL1/MRP2 mediates neurite outgrowth in a glycogen synthase kinase 3beta-dependent manner. Mol Cell Biol. 2006; 26(22):8371-84. PMC: 1636797. DOI: 10.1128/MCB.02167-05. View

19.

Watson P, Arora V, Sawyers C . Emerging mechanisms of resistance to androgen receptor inhibitors in prostate cancer. Nat Rev Cancer. 2015; 15(12):701-11. PMC: 4771416. DOI: 10.1038/nrc4016. View

20.

Siegel R, Miller K, Jemal A . Cancer statistics, 2020. CA Cancer J Clin. 2020; 70(1):7-30. DOI: 10.3322/caac.21590. View